Table 1.
Patients characteristics (n = 38), for the whole cohort and according to the presence of ≤3 FLs or >3 FLs on PET/CT.
| Characteristics | All Patients n = 38 | PET ≤ 3 FLs n = 19 | PET > 3 FLs n = 19 | p |
|---|---|---|---|---|
| Clinical characteristics at relapse | ||||
| Age, median (range) | 73 (58–87) | 75 (62–87) | 69 (58–87) | 0.58 |
| Age > 75 years, n (%) | 17 (45) | 10 (53) | 7 (37) | 0.51 |
| Sex ratio male/female | 1 (19/19) | 0.7 (8/11) | 1.37 (11/8) | 0.52 |
| Biological parameters at relapse | ||||
| dFLC mg/L, median (IQR) * | 180 (18–946) | 85 (10–437) | 206 (103–1142) | 0.08 |
| Abnormal FLC ratio, n (%) * | 25 (66) | 11 | 14 | 0.29 |
| High FLC ratio (>120), n (%) | 6 (16) | 1 | 5 | 0.18 |
| Creatinine clearance < 60 mL/min | 14 (37) | 7 | 7 | 1 |
| Hemoglobin < 10 g/dL, n (%) | 11 (29) | 3 | 8 | 0.15 |
| β2microglobulin (mg/L) * | 3.67 (1.3–14.2) | 2.75 (1.3–9.6) | 4.13 (1.8–19) | 0.015 |
| Elevated LDH, n (%) | 12 (32) | 6 | 6 | 1 |
| Initial myeloma characteristics | ||||
| Isotype | ||||
| IgG, n (%) | 21 (55) | 10 | 11 | 0.95 |
| IgA, n (%) | 8 (21) | 4 | 4 | |
| Light chain only (kappa), n (%) | 9 (24) | 5 | 4 | |
| ISS stage | ||||
| ISS 1, n (%) | 16 (42) | 12 | 4 | 0.028 |
| ISS 2, n (%) | 14 (37) | 5 | 9 | |
| ISS 3, n (%) | 8 (21) | 2 | 6 | |
| Cytogenetics | ||||
| High-risk cytogenetics, n (%) | 8 (21) | 2 | 6 | 0.24 |
| No High-risk cytogenetics, n (%) | 25 (66) | 13 | 12 | |
| Missing | 5 (13) | 4 | 1 | |
| Therapy | ||||
| Line of therapy before antiCD38 | 3 (2–10) | 3 (2–4) | 3 (2–10) | 0.48 |
| >2 previous lines of therapy, n (%) | 20 (53) | 10 | 10 | 1 |
| ASCT transplantation, n (%) | 18 (47%) | 8 | 10 | 0.74 |
| Type of anti-CD38 | ||||
| Daratumumab, n (%) | 32 (84) | 18 | 14 | 0.18 |
| Isatuximab, n (%) | 6 (16) | 1 | 5 | |
| Associated treatment | ||||
| Corticosteroids only, n (%) | 7 (18) | 2 | 5 | 0.40 |
| ImiD, n (%) | 19 (50) | 10 | 9 | 1 |
| Proteasome inhibitor, n (%) | 10 (26) | 6 | 4 | 0.71 |
| Other, n (%) 1 | 4 (11) | 1 | 3 | 0.60 |
1 Chemotherapy (2), Azacitidine for concomitant MDS (1), Trametinib (1). ASCT: Autologous stem cell transplantation FLC: serum immunoglobulin-free light chain. * missing data.